Professional Documents
Culture Documents
Go bucket
Poly medicure A health care company into health care disposables. Currently growing in double
digits with this years topline likely to be around 80-85 Crs and net profit to be between 7-8 Crs. The
ROE is 20% plus range and the entire company is selling at around 75 Crs, with a PE of around 8.
Had a brief look at their website and was unimpressed. No annual report or financial available on the
company website. Worth further investigation for the time being
Ultramarine and pigments A small company into dyes and pigments with an annual turnover of
around 60-70 Crs which has been stagnant for the last 4-5 years. Net profits have zoomed from 4 Cr
to almost 18 Crs (expected) for the current year. Capital invested in the business has come down in
the meantime with investments on the balance sheet of around 25 Crs (FY 2005) and low debt of
around 5 Crs. Capital requirements in the business seem to be low and hence the business seems
to have good free cash flow and a return on invested capital of almost 50%. Definitely worth a closer
look.
next post : i would be listing more ideas in both the buckets
ps : Please see my disclaimer. I would not want anyone to lose money based on my analysis
MARCH 9, 2007
investments)
The company has a net investment on the balance sheet of 500 Cr (net of debt). If I knock off the
investment value of 28 Rs per share, then the valuation comes to around 5 PE based on the current
market price. The stock seems to be a compelling buy.
Reason for rejection
On analysing the consolidated balance sheet, I discovered that the company has an additional debt
of 500 Crs on its books due to a JV. The company has converted Cholamandalam investment and
finance co. (CIFCL) into a JV with DBS bank. As a result the JV debts is now on the books. The
company has however not provided any details further on this event. I think the event is important
enough for the company to provide more details and give an assesment on the risks.
The above reason may seem small, but the debt and corresponding risk changes the profile of the
company. The D/E ratio is now 1.3:1 and the company has not even provided enough details of the
new JV. As a result I have decided to give the company a pass for the time being.
MARCH 6, 2007